Capitainer launches DIP70 – a new device for dried urine microsampling

Stockholm, Sweden, October 29, 2025 – Capitainer today announced the launch of Capitainer®DIP70, a new volumetric device designed to simplify and standardize remote urine sampling. The device automatically collects two precisely metered 70 µL samples in dried format, enabling convenient and hygienic sampling at home or in clinical and research settings. 

The drying process allows samples to be shipped by regular mail without the need for cold chain logistics, while minimizing the risk of microbial growth and analyte degradation. This makes Capitainer®DIP70 a robust and cost-effective solution for decentralized studies, toxicology, internal medicine, and other research or clinical applications where sample integrity and stability are critical. 

“With DIP70, we’re expanding our self-sampling portfolio beyond blood and plasma,” said Christopher Aulin, CEO at Capitainer. “In many cases, both blood and urine samples are needed to provide neccessary information, and Capitainer can now offer a complete solution for decentralized sampling.” 

Capitainer®DIP70 – key benefits: 

• Accurate: Automatically meters 2 × 70 µL of urine 

• User-friendly: Simply dip to collect the sample 

• Hygienic: No need to handle urine tubes 

• Cost-efficient shipping: Fits in standard envelopes for easy postal transport 

• Stable: Dried format minimizes sample contamination by unwanted microbial growth during shipment 

Capitainer®DIP70 empowers healthcare providers, researchers, and laboratories to implement accurate, convenient, and sustainable urine sampling workflows – from collection to analysis. 

For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Email: christopher.aulin@capitainer.com

About Capitainer
Capitainer AB is a Swedish MedTech company that develops and sells patient-centric solutions for self-sampling of blood, plasma, and urine. Founded in 2016, Capitainer has developed unique technologies for collecting and drying exact volumes of fluid within easy-to-use sampling cards. These cards may be sent as standard post to relevant testing laboratories, thus bypassing the need for cold chain logistics and specialised packaging. Capitainer’s products are market-leading with respect to precision and accuracy, with demonstrated equal performance to established pipetting methods. The products are applicable within several market segments, including but not limited to, clinical biomarkers, therapeutic drug monitoring, genomics, drug abuse and doping testing, and R&D and clinical studies.